Prescient Chief Scientific Officer Named Among Top 20 Translational Researchers by Nature

1st September 2015, ASX Announcement

Prescient Therapeutics (ASX:PTX), a clinical stage oncology company, is pleased to announce that its Chief Scientific Officer and co-investor of PTX’s technologies, Professor Said Sebti, has been named as one of the Top 20 Translational Researchers in the world by the prestigious science publisher Nature Publishing Group.

Professor Sebti has been ranked alongside Nobel laureate Dr David Baltimore on the internationally regarded list, which is complied by patent analytics firm IP Checkups following examination of 2014’s most active scientists for patenting.

Scientists are included on the list following examination of each researcher’s most-cited patent from the previous five years and their ‘H index’, which is a score based on the impact of published work.

As well as overseeing Prescient’s oncology programs, Professor Sebti is the Manuel and Adeline Garcia Endowed Professor and Chair, Department for Drug Discovery, at the Moffitt Cancer Center in Florida; a National Cancer Institute-designated comprehensive cancer center, and one of the largest cancer centers in the US.

To read the full announcement, please click here.